Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Gibson CJ, et al. Among authors: madero marroquin r. J Clin Oncol. 2022 Jan 10;40(2):189-201. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793200 Free PMC article.
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Menghrajani K, et al. Among authors: madero marroquin r. Blood Adv. 2022 Jan 8;6(3):828-847. doi: 10.1182/bloodadvances.2021004881. Blood Adv. 2022. PMID: 34551064 Free PMC article.
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, DeZern AE, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Lauring J, Park BH. Dalton WB, et al. Among authors: madero marroquin r. J Clin Invest. 2019 Aug 8;129(11):4708-4723. doi: 10.1172/JCI125022. J Clin Invest. 2019. PMID: 31393856 Free PMC article.
Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J, Madero-Marroquin R, Zubizarreta N, Moshier E, Tremblay D, Coltoff A, Lancman G, Fuller R, Rana M, Mascarenhas J, Jacobs SE. Caro J, et al. Among authors: madero marroquin r. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):903-911. doi: 10.1016/j.clml.2022.08.001. Epub 2022 Aug 7. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36109322
Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.
Lau BW, Huh K, Madero-Marroquin R, De Marchi F, Lim Y, Wang Q, Lobo F, Marchionni L, Smith DB, DeZern A, Levis MJ, Aplan PD, Matsui W, Gondek LP. Lau BW, et al. Among authors: madero marroquin r. Oncogene. 2019 Jan;38(5):687-698. doi: 10.1038/s41388-018-0431-9. Epub 2018 Aug 31. Oncogene. 2019. PMID: 30171262 Free PMC article.
An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction Chemotherapy.
Tremblay D, Madero-Marroquin R, Lancman G, Coltoff A, Feld J, Caro J, Sherlock E, Keyzner A, Navada S, Silverman LR, Moshier E, Zubizarreta N, Mascarenhas J. Tremblay D, et al. Among authors: madero marroquin r. J Palliat Med. 2020 Nov;23(11):1424-1425. doi: 10.1089/jpm.2020.0355. J Palliat Med. 2020. PMID: 33174777 No abstract available.